Logo

GeneFrontier to Make, Market Abcellute's Hepatocyte Tech to Japanese Drug Makers

Nov 27, 2006
NEW YORK (GenomeWeb News) — Welsh research company Abcellute today said it has signed an exclusive deal with microarray service provider GeneFrontier to manufacture, market, and distribute Abcellute’s hepatocyte cell-preservation products in Japan.
 
The agreement also gives Tokyo-based GeneFrontier rights to pen sub-license deals with the technology with pharma companies.    
 
Abcellute said its cell-preservation technology allows drug developers to evaluate drugs using hepatocytes that may be kept at non-freezing temperatures throughout a working week.
 
Financial terms of the deal were not released.

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.